ABSTRACT
Dietary supplementation with B-vitamins that lower plasma total homocysteine concentrations are expected to lower the risk of cardiovascular disease. Folic acid and vitamin B12 lower blood homocysteine concentrations by about 25-30% in populations without folic acid fortification, but by only 10-15% in populations with fortification. In observational studies, 25% lower homocysteine is associated with about 10% less coronary heart disease (CHD) and about 20% less stroke. This review examines the current status of 12 large-scale randomized trials of B-vitamin supplementation and risk of cardiovascular disease. Seven of these trials are being performed in populations without fortification (five involving participants with prior CHD, two with prior stroke) and five in populations with fortification (two with prior CHD, two with renal disease, and one with prior stroke). Many of these trials may not have included a sufficient number of people or lasted long enough to have adequate power to exclude false-negative results. Taken together, however, these trials involve 32,000 patients with prior vascular disease in unfortified populations and 20,000 (14,000 with vascular disease and 6000 with renal disease) patients in fortified populations. A metaanalysis of these trials should have adequate power to determine whether homocysteine-lowering vitamin supplements can reduce the risk of cardiovascular disease.
KEYWORDS
Folic acid - vitamin B12
- trials - cardiovascular disease
REFERENCES
-
1
McCully K S.
Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.
Am J Pathol.
1969;
56(1)
111-128
-
2 Mudd S H, Levy H L, Skovby F. Disorders of transulfuration. In: Scriver CR, Baudet AL, Sly WS, et al.,
The Metabolic and Molecular Bases of Inherited Disease, 8th ed New York; McGraw-Hill 1995: 1279-1327
-
3
Selhub J, Jacques P F, Wilson P W, Rush D, Rosenberg I H.
Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.
JAMA.
1993;
270
2693-2698
-
4
Homocysteine Studies Collaboration .
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.
JAMA.
2002;
288
2015-2222
-
5
Homocysteine Lowering Trialists' Collaboration .
Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials.
BMJ.
1998;
316
894-898
-
6
Jacques P F, Selhub J, Bostom A G, Wilson P WF, Rosenberg I H.
The effect of folic acid fortification on plasma folate and total homocysteine concentrations.
N Engl J Med.
1999;
340
1449-1454
-
7
Bostom A G, Liaugaudas G, Jacques P F, Rosenberg I H, Selhub J.
Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid fortified cereal grain flour.
Arterioscler Thromb Vasc Biol.
2002;
22
488-491
-
8
Beaulieu A J, Gohh R Y, Han H et al..
Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients.
Arterioscler Thromb Vasc Biol.
1999;
19
2918-2921
-
9
Wilcken D E, Wilcken B.
The pathogenesis of coronary artery disease. A possible role for methionine metabolism.
J Clin Invest.
1976;
57(4)
1079-1082
-
10
Brattstrom L E, Hardebo J E, Hultberg B L.
Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease.
Stroke.
1984;
15(6)
1012-1016
-
11
Boers G H, Smals A G, Trijbels F J et al..
Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.
N Engl J Med.
1985;
313(12)
709-715
-
12
Clarke R, Daly L, Robinson K et al..
Hyperhomocysteinemia: an independent risk factor for vascular disease.
N Engl J Med.
1991;
324(17)
1149-1155
-
13
Genest Jr J J, McNamara J R, Salem D N, Wilson P W, Schaefer E J, Malinow M R.
Plasma homocyst(e)ine levels in men with premature coronary artery disease.
J Am Coll Cardiol.
1990;
16(5)
1114-1119
-
14
Pancharuniti N, Lewis C A, Sauberlich H E et al..
Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease.
Am J Clin Nutr.
1994;
59(4)
940-948
-
15
von Eckardstein A, Malinow M R, Upson B et al..
Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men.
Arterioscler Thromb.
1994;
14(3)
460-464
-
16
Hopkins P N, Wu L L, Wu J et al..
Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease.
Arterioscler Thromb Vasc Biol.
1995;
15(9)
1314-1320
-
17
Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson B B.
Plasma homocysteine in the acute and convalescent phases after stroke.
Stroke.
1995;
26(5)
795-800
-
18
Malinow M R, Ducimetiere P, Luc G et al..
Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease.
Atherosclerosis.
1996;
126(1)
27-34
-
19
Graham I M, Daly L E, Refsum H M et al..
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.
JAMA.
1997;
277(22)
1775-1781
-
20
Silberberg J, Crooks R, Fryer J et al..
Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading.
Atherosclerosis.
1997;
133(1)
105-110
-
21
Schwartz S M, Siscovick D S, Malinow M R et al..
Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene.
Circulation.
1997;
96(2)
412-417
-
22
Joubran R, Asmi M, Busjahn A, Vergopoulos A, Luft F C, Jouma M.
Homocysteine levels and coronary heart disease in Syria.
J Cardiovasc Risk.
1998;
5(4)
257-261
-
23
Chambers J C, Obeid O A, Refsum H et al..
Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men.
Lancet.
2000;
355(9203)
523-527
-
24
Coull B M, Malinow M R, Beamer N, Sexton G, Nordt F, de Garmo P.
Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke.
Stroke.
1990;
21(4)
572-576
-
25
Dalery K, Lussier Cacan S, Selhub J, Davignon J, Latour Y, Genest Jr J.
Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate.
Am J Cardiol.
1995;
75(16)
1107-1111
-
26
Robinson K, Mayer E L, Miller D P et al..
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease.
Circulation.
1995;
92(10)
2825-2830
-
27
Lolin Y I, Sanderson J E, Cheng S K et al..
Hyperhomocysteinaemia and premature coronary artery disease in the Chinese.
Heart.
1996;
76(2)
117-122
-
28
Evers S, Koch H G, Grotemeyer K H, Lange B, Deufel T, Ringelstein E B.
Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia.
Arch Neurol.
1997;
54(10)
1276-1282
-
29
Boushey C J, Beresford S A, Omenn G S, Motulsky A G.
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.
JAMA.
1995;
274(13)
1049-1057
-
30
Danesh J, Lewington S.
Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies.
J Cardiovasc Risk.
1998;
5(4)
229-232
-
31
Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J.
A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.
Stroke.
1994;
25
1924-1930
-
32
Verhoef P, Stampfer M J, Buring J E et al..
Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate.
Am J Epidemiol.
1996;
143(9)
845-859
-
33
Verhoef P, Kok F J, Kruyssen D A et al..
Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis.
Arterioscler Thromb Vasc Biol.
1997;
17(5)
989-995
-
34
Alfthan G, Pekkanen J, Jauhiainen M et al..
Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.
Atherosclerosis.
1994;
106(1)
9-19
-
35
Arnesen E, Refsum H, Bonaa K H, Ueland P M, Forde O H, Nordrehaug J E.
Serum total homocysteine and coronary heart disease.
Int J Epidemiol.
1995;
24(4)
704-709
-
36
Perry I J, Refsum H, Morris R W, Ebrahim S B, Ueland P M, Shaper A G.
Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men.
Lancet.
1995;
346(8987)
1395-1398
-
37
Evans R W, Shaten B J, Hempel J D, Cutler J A, Kuller L H.
Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial.
Arterioscler Thromb Vasc Biol.
1997;
17(10)
1947-1953
-
38
Ubbink J B, Fehily A M, Pickering J, Elwood P C, Vermaak W J.
Homocysteine and ischaemic heart disease in the Caerphilly cohort.
Atherosclerosis.
1998;
140(2)
349-356
-
39
Stehouwer C D, Weijenberg M P, van den Berg M, Jakobs C, Feskens E J, Kromhout D.
Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up.
Arterioscler Thromb Vasc Biol.
1998;
18(12)
1895-1901
-
40
Folsom A R, Nieto F J, McGovern P G et al..
Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.
Circulation.
1998;
98(3)
204-210
-
41
Wald N J, Watt H C, Law M R, Weir D G, McPartlin J, Scott J M.
Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention.
Arch Intern Med.
1998;
158(8)
862-867
-
42
Bots M L, Launer L J, Lindemans J et al..
Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study.
Arch Intern Med.
1999;
159(1)
38-44
-
43
Whincup P H, Refsum H, Perry I J et al..
Serum total homocysteine and coronary heart disease: Prospective study in middle aged men.
Heart.
1999;
82(4)
448-454
-
44
Clarke R, Lewington S, Donald A et al..
Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
J Cardiovasc Risk.
2001;
8
363-369
-
45
Clarke R, Shipley M, Lewington S et al..
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.
Am J Epidemiol.
1999;
150
341-353
-
46
Bostom A G, Silbershatz H, Rosenberg I H et al..
Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women.
Arch Intern Med.
1999;
159(10)
1077-1080
-
47
Kark J D, Selhub J, Adler B et al..
Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem.
Ann Intern Med.
1999;
131
321-330
-
48
Voutilainen S, Lakka T A, Hamelahti P, Lehtimaki T, Poulsen H E, Salonen J T.
Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study.
J Intern Med.
2000;
248
217-222
-
49
Vollset S E, Refsum H, Tverdal A et al..
Plasma total homocysteine and cardiovascular disease and noncardiovascular mortality: the Hordaland Homocysteine Study.
Am J Clin Nutr.
2001;
74
130-136
-
50
Knekt P, Reunanen A, Alfthan G et al..
Hyperhomocysteinemia: a risk factor or consequence of coronary heart disease?.
Arch Intern Med.
2001;
161
1589-1594
-
51
Ridker P M, Manson J E, Buring J E, Shih J, Matias M, Hennekens C H.
Homocysteine and risk of cardiovascular disease among post-menopausal women.
JAMA.
1999;
281
1817-1821
-
52
Davey Smith G.
“Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease?.
Int J Epidemiol.
2003;
32
1-22
-
53
Klerk M, Verhoef P, Clarke R et al..
MTHFR 677TC→t polymorphism and risk of coronary heart disease: a meta-analysis.
JAMA.
2002;
288
2023-2031
-
54
Jacques P F, Bostom A G, Williams R R et al..
Relation between folate status, a common mutation between methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.
Circulation.
1996;
93
7-9
-
55
Wald D S, Law M, Morris J K.
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.
BMJ.
2002;
325
1202-1206
-
56
Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A.
Homocysteine and stroke: evidence on a causal link from mendelian randomization.
Lancet.
2005;
365
224-232
-
57
Thambyrajah J, Landray M J, McGlynn F J, Jones H J, Wheeler D C, Townend J N.
Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?.
Circulation.
2000;
102
871-875
-
58
Schnyder G, Roffi M, Flammer Y, Pin R, Hess O M.
Effect of homocysteine-lowering therapy with folic acid, vitamin B(12) and vitamin B(6) on clinical outcome after percutaneous coronary intervention: The Swiss Heart Study: a randomized controlled trial.
JAMA.
2002;
288
973-979
-
59
Schnyder G, Roffi M, Pin R et al..
Decreased rate of coronary restenosis after lowering of plasma homocysyteine levels.
N Engl J Med.
2001;
345
1593-1600
-
60
Baker F, Picton D, Blackwood S et al..
Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial.
Circulation.
2002;
106
A3642
-
61
The VITATOPS Study Group .
The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and design of an international large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke.
Cerebrovasc Dis.
2002;
13
120-126
-
62
Toole J F, Malinow M R, Chambless L E et al..
Lowering homocysteine in patients with ischemic stroke to prevent recrurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
JAMA.
2004;
291
565-575
Dr.
Robert Clarke
Clinical Trial Service Unit and Epidemiological Studies Unit
Nuffield Department of Clinical Medicine, Radcliffe Infirmary
Oxford OX2 6HE, United Kingdom
